Protein-protein interactions as targets for small molecule drug discovery.

Protein-protein interactions represent a highly populated class of targets for drug discovery. However, such systems present a number of unique challenges. This review presents an analysis of individual protein-protein interaction systems which have recently yielded success in discovering drug-like inhibitors. The structural characteristics of the protein binding sites and the attributes of the small molecule ligands are focused upon, in an attempt to derive commonly shared principles that may be of general usefulness in future drug discovery efforts within this target class.

[1]  N. Sigal,et al.  Allosteric inhibitors of inducible nitric oxide synthase dimerization discovered via combinatorial chemistry. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[2]  L. Vassilev,et al.  Targeting protein–protein interactions for cancer therapy , 2005, Journal of Molecular Medicine.

[3]  R. Gould,et al.  Non-peptide GPIIb/IIIa inhibitors. 20. Centrally constrained thienothiophene alpha-sulfonamides are potent, long acting in vivo inhibitors of platelet aggregation. , 1999, Journal of medicinal chemistry.

[4]  R. Campbell,et al.  N-acyl-L-phenylalanine derivatives as potent VLA-4 antagonists that mimic a cyclic peptide conformation. , 2002, Bioorganic & medicinal chemistry letters.

[5]  Stephen F. Betz,et al.  Structural basis for binding of Smac/DIABLO to the XIAP BIR3 domain , 2000, Nature.

[6]  Barry S. Coller,et al.  Structural basis for allostery in integrins and binding to fibrinogen-mimetic therapeutics , 2004, Nature.

[7]  J. A. Grant,et al.  A shape-based 3-D scaffold hopping method and its application to a bacterial protein-protein interaction. , 2005, Journal of medicinal chemistry.

[8]  L. Vassilev,et al.  In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2 , 2004, Science.

[9]  G. Schneider,et al.  Mapping of proteinase active sites by projection of surface‐derived correlation vectors , 1999 .

[10]  I D Campbell,et al.  The solution structure of the F42A mutant of human interleukin 2. , 1995, Journal of molecular biology.

[11]  P. Hajduk,et al.  Discovery of a potent inhibitor of the antiapoptotic protein Bcl-xL from NMR and parallel synthesis. , 2006, Journal of medicinal chemistry.

[12]  N. Fotouhi,et al.  The discovery of VLA-4 antagonists. , 2004, Current topics in medicinal chemistry.

[13]  G. Ju,et al.  Localization in human interleukin 2 of the binding site to the alpha chain (p55) of the interleukin 2 receptor. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[14]  D. Lane,et al.  Immunochemical analysis of the interaction of p53 with MDM2;--fine mapping of the MDM2 binding site on p53 using synthetic peptides. , 1994, Oncogene.

[15]  T. Rush,et al.  Design and synthesis of indolo[2,3-a]quinolizin-7-one inhibitors of the ZipA-FtsZ interaction. , 2004, Bioorganic & medicinal chemistry letters.

[16]  D D Gretler,et al.  Platelet glycoprotein IIb-IIIa antagonists as prototypical integrin blockers: novel parenteral and potential oral antithrombotic agents. , 2000, Journal of medicinal chemistry.

[17]  Maxwell D Cummings,et al.  Discovery and cocrystal structure of benzodiazepinedione HDM2 antagonists that activate p53 in cells. , 2005, Journal of medicinal chemistry.

[18]  G. Powers,et al.  Identification of a Small Molecule Inhibitor of the IL-2/IL-2Rα Receptor Interaction Which Binds to IL-2 , 1997 .

[19]  I. Campbell,et al.  Secondary structure of human interleukin 2 from 3D heteronuclear NMR experiments. , 1992, Biochemistry.

[20]  P. Reinemer,et al.  Crystal Structure of the Interleukin-4/Receptor α Chain Complex Reveals a Mosaic Binding Interface , 1999, Cell.

[21]  S. Korsmeyer,et al.  An inhibitor of Bcl-2 family proteins induces regression of solid tumours , 2005, Nature.

[22]  Thomas Rawson,et al.  From Peptide to Non-Peptide. 2. The de Novo Design of Potent, Non-peptidal Inhibitors of Platelet Aggregation Based on a Benzodiazepinedione Scaffold , 1994 .

[23]  Saul H Rosenberg,et al.  Discovery of potent antagonists of the antiapoptotic protein XIAP for the treatment of cancer. , 2004, Journal of medicinal chemistry.

[24]  D. Nowlin,et al.  A novel cyclic pentapeptide inhibits alpha 4 beta 1 and alpha 5 beta 1 integrin-mediated cell adhesion. , 1993, The Journal of biological chemistry.

[25]  John W. Bean,et al.  Direct design of a potent non-peptide fibrinogen receptor antagonist based on the structure and conformation of a highly constrained cyclic RGD peptide , 1993 .

[26]  S. Sprang,et al.  Cytokine structural taxonomy and mechanisms of receptor engagement , 1993 .

[27]  D. Mckay,et al.  Three-dimensional structure of interleukin-2. , 1987, Science.

[28]  Jun Wang,et al.  Small-Molecule Inhibition of TNF-α , 2005, Science.

[29]  M. Arkin,et al.  Identification of nonpeptidic small-molecule inhibitors of interleukin-2. , 2005, Bioorganic & medicinal chemistry letters.

[30]  Michelle R Arkin,et al.  Discovery of a potent small molecule IL-2 inhibitor through fragment assembly. , 2003, Journal of the American Chemical Society.

[31]  R. Meadows,et al.  Structure of Bcl-xL-Bak Peptide Complex: Recognition Between Regulators of Apoptosis , 1997, Science.

[32]  T. Clackson,et al.  A hot spot of binding energy in a hormone-receptor interface , 1995, Science.

[33]  N. Fotouhi,et al.  The design and synthesis of potent cyclic peptide VCAM-VLA-4 antagonists incorporating an achiral Asp-Pro mimetic. , 2000, Bioorganic & medicinal chemistry letters.

[34]  E B Reilly,et al.  Discovery of potent antagonists of leukocyte function-associated antigen-1/intercellular adhesion molecule-1 interaction. 3. Amide (C-ring) structure-activity relationship and improvement of overall properties of arylthio cinnamides. , 2001, Journal of medicinal chemistry.

[35]  D. Fry,et al.  NMR characterization of interleukin‐2 in complexes with the IL‐2Rα receptor component, and with low molecular weight compounds that inhibit the IL‐2/IL‐Rα interaction , 2003, Protein science : a publication of the Protein Society.

[36]  R J Lynch,et al.  Non-peptide fibrinogen receptor antagonists. 1. Discovery and design of exosite inhibitors. , 1992, Journal of medicinal chemistry.

[37]  Claus Ehrhardt,et al.  1,4-Diazepane-2-ones as novel inhibitors of LFA-1. , 2003, Bioorganic & medicinal chemistry letters.

[38]  A. Levine,et al.  Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain , 1996, Science.

[39]  L. Vassilev,et al.  Development of E3-substrate (MDM2-p53)-binding inhibitors: structural aspects. , 2005, Methods in enzymology.

[40]  Michelle R. Arkin,et al.  Binding of small molecules to an adaptive protein–protein interface , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[41]  Thilo Stehle,et al.  Crystal Structure of the Extracellular Segment of Integrin αVβ3 in Complex with an Arg-Gly-Asp Ligand , 2002, Science.

[42]  J. Tainer,et al.  Structure of nitric oxide synthase oxygenase dimer with pterin and substrate. , 1998, Science.

[43]  M. J. Fisher,et al.  Non-peptide RGD surrogates which mimic a Gly-Asp beta-turn: potent antagonists of platelet glycoprotein IIb-IIIa. , 1997, Journal of medicinal chemistry.

[44]  R. Kriwacki,et al.  Structural basis for LFA-1 inhibition upon lovastatin binding to the CD11a I-domain. , 1999, Journal of molecular biology.

[45]  Yan Zhang,et al.  The bacterial cell‐division protein ZipA and its interaction with an FtsZ fragment revealed by X‐ray crystallography , 2001, The EMBO journal.

[46]  J. Kallen,et al.  Improved Lymphocyte Function-associated Antigen-1 (LFA-1) Inhibition by Statin Derivatives , 2004, Journal of Biological Chemistry.

[47]  Junichi Takagi,et al.  Structures of the αL I Domain and Its Complex with ICAM-1 Reveal a Shape-Shifting Pathway for Integrin Regulation , 2003, Cell.

[48]  Yigong Shi,et al.  Molecular targeting of inhibitor of apoptosis proteins based on small molecule mimics of natural binding partners. , 2002, Biochemistry.

[49]  K. Christopher Garcia,et al.  The Structure of Interleukin-2 Complexed with Its Alpha Receptor , 2005, Science.

[50]  R. Gould,et al.  Nonpeptide GPIIb/IIIa inhibitors. 10. Centrally constrained alpha-sulfonamides are potent inhibitors of platelet aggregation , 1996 .

[51]  David C Fry,et al.  NMR structure of a complex between MDM2 and a small molecule inhibitor , 2004, Journal of biomolecular NMR.

[52]  T. Ceska,et al.  Structure of an allosteric inhibitor of LFA-1 bound to the I-domain studied by crystallography, NMR, and calorimetry. , 2004, Biochemistry.